United Therapeutics (UTHR -1.4%) is teaming up with 3D Systems (DDD +1.8%) on a deal where the two will work toward "printing" the outline of human organs, eventually creating parts from a person's own cells.
3D Systems chief Vyomesh Joshi says it will first work with United' Lung Biotechnology PBC unit to create a "scaffolding" for human lungs.
"By cellularizing scaffolds created with 3D Systems printers with a patient's own cells, there will no longer be a need for immunosuppression and a vastly greater number of patients can extend their enjoyment of life through organ transplantation," says United Therapeutics CEO Martine Rothblatt.
Most of the work will take place in a new bioprinting lab that 3D Systems has in San Diego.
Previously: United Therapeutics Q1 non-GAAP EPS up 24% (Apr. 26 2017)